The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
Open accessAbstract
Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (> or = 25%) improvement in SS14 score between baseline and 2 months sustained for > or =4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters. The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t-test). A sustained (> or = 4 weeks) improvement (> or =25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson's chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13-27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6-7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0-7.9) (log-rank, P = 0.84) for BSC patients, and 1 -year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Stephens, R. J., Hopwood, P., Girling, D. J., & Machin, D. (1997) · Quality of Life Research · doi:10.1023/a:1026458604826 · Cited by 241
Self-citationAapro, M. S., Martin, C., & Hatty, S. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199803000-00001 · Cited by 228
on behalf of the Medical Research Council (MRC) Lung Cancer Working Party, Hopwood, P., & Stephens, R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.124 · Cited by 192
Self-citationHopwood, P., Stephens, R. J., & Machin, D. (1994) · Quality of Life Research · doi:10.1007/bf00451726 · Cited by 118
Self-citationStephens, R. J., Hopwood, P., & Girling, D. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690085 · Cited by 71
Self-citationQuality of Life During Chemotherapy in Non-Small Cell Lung Cancer Patients
Fernández, C. H., Rosell, R., Abad-Esteve, A., Monras, P., Moreno, I., Serichol, M., & Roviralta, M. (1989) · Acta Oncologica · doi:10.3109/02841868909111177 · Cited by 70
Bleehen, N. M., Girling, D. J., Hopwood, P., Lallemand, G., Machin, D., Stephens, R. J., & Bailey, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.71 · Cited by 55
Self-citationThatcher, N., Hopwood, P., & Anderson, H. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00336-x · Cited by 54
Self-citationBatel-Copel, L., Kornblith, A. B., Batel, P. C., & Holland, J. C. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00414-5 · Cited by 42
The MIC regimen in non-small cell lung cancer
Cullen, M. H. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90173-u · Cited by 30
Aaronson, N. K. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)96384-8 · Cited by 19
Stephens, R. J. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)98947-9 · Cited by 7
Self-citation
Cited by
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Vickers, A. J. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-6 · Cited by 559
Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P., Demetri, G. D., Sarokhan, B. J., Slavin, M. B., & Glaspy, J. A. (2002) · Cancer · doi:10.1002/cncr.10763 · Cited by 428
Role of gemcitabine in cancer therapy
Toschi, L., Finocchiaro, G., Bartolini, S., Gioia, V, & Cappuzzo, F. (2005) · Future Oncology · doi:10.1517/14796694.1.1.7 · Cited by 373
Smit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Metadata
- Authors
- Anderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., Milroy, R., Maughan, T. S., Falk, S. J., Bond, M. G., Burt, P. A., Connolly, C. K., McIllmurray, M. B., & Carmichael, J.
- Venue
- British Journal of Cancer
- Published
- 2000-08
- Volume
- 83
- Issue
- 4
- Pages
- 447-453
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1483985834
- Cited by
- 338
- References
- 18
- FWCI
- 28.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.